Compare · MRNA vs PTHS
MRNA vs PTHS
Side-by-side comparison of Moderna Inc. (MRNA) and Pelthos Therapeutics Inc. (PTHS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and PTHS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $24.53B, about 261.5x PTHS ($93.8M).
- MRNA has been more active in the news (11 items in the past 4 weeks vs 5 for PTHS).
- MRNA has more recent analyst coverage (25 ratings vs 6 for PTHS).
- Company
- Moderna Inc.
- Pelthos Therapeutics Inc.
- Price
- -
- -
- Market cap
- $24.53B
- $93.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- AMEX
- IPO
- 2018
- 2024
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 6
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- President Hoge Stephen exercised 53,336 shares at a strike of $19.15 and sold $3,605,514 worth of shares (53,336 units at $67.60) as part of a pre-agreed trading plan (SEC Form 4)
- Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
Latest PTHS
- Director Friedberg Ezra M sold $14,556 worth of shares (558 units at $26.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 81,042 units (SEC Form 4) to cover withholding tax
- Director Pauls Matthew sold $20,561 worth of shares (786 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 14,364 units (SEC Form 4) to satisfy withholding tax
- Director Greenleaf Peter sold $20,827 worth of shares (797 units at $26.13) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 23,884 units (SEC Form 4) to satisfy withholding tax
- Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Director Friedberg Ezra M sold $7,724 worth of shares (283 units at $27.29) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 81,600 units (SEC Form 4) to satisfy tax liability
- Director Davis Todd C bought $999,983 worth of shares (35,948 units at $27.82), increasing direct ownership by 90% to 75,834 units (SEC Form 4)
- Pelthos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
- CFO, Treas & Secty Francis Knuettel Ii returned 13,947 shares to the company and sold $40,265 worth of shares (1,500 units at $26.84), decreasing direct ownership by 42% to 19,525 units (SEC Form 4)